Mirum Pharmaceuticals to Present at Two Key Investor Conferences This Month
Event summary
- Mirum Pharmaceuticals will participate in two investor conferences in May 2026: H.C. Wainwright's BioConnect on May 19 and RBC Capital Markets' Global Healthcare on May 20.
- Both events feature live webcasted fireside chats, with replays available afterward.
- Mirum focuses on rare liver and genetic diseases, with a portfolio including LIVMARLI, CHOLBAM, and CTEXLI.
- The company's pipeline includes late-stage candidates for PSC, PBC, HDV, FOP, and FXS.
The big picture
Mirum Pharmaceuticals' participation in these investor conferences comes as the rare disease sector sees heightened interest from both investors and regulators. The company's focus on underserved conditions positions it in a niche market with high unmet medical needs. With multiple late-stage candidates in development, Mirum is poised to potentially expand its commercial portfolio, which could drive significant growth if clinical and regulatory milestones are met.
What we're watching
- Pipeline Progress
- How Mirum's late-stage candidates will impact its rare disease portfolio and market positioning.
- Investor Sentiment
- Whether the upcoming presentations will shift market perception of Mirum's growth trajectory.
- Regulatory Milestones
- The pace at which zilurgisertib advances through FDA review for fibrodysplasia ossificans progressiva.